IRadimed Corporation (NASDAQ:IRMD) Q4 2023 Earnings Conference Call February 8, 2024 9:00 AM ET
Company Participants
Roger Susi - President and Chief Executive Officer
Jack Glenn - Chief Financial Officer
Conference Call Participants
Frank Takkinen - Lake Street Capital Markets
Frank DiLorenzo - Singular Research
Operator
Welcome to the IRadimed Corporation Fourth Quarter of 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, February 8, 2024, and contains time-sensitive information that is accurate only today.
Earlier, IRadimed released its financial results for the fourth quarter of 2024. A copy of this press release announcing the company's earnings is available under the heading News on their website at iradimed.com. A press release copy was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov.
This call is being broadcast live over the Internet on the company's website at iradimed.com, and a replay of the call will be available on the website for the next 90 days.
Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans and events and may include the company's expected future results.
IRadimed reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained free from SEC's website at sec.gov.
I would now like to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi?
Roger Susi
Thank you, operator. Good morning, and thank you for joining us on today's call.
I'm very happy to report our 10th consecutive record quarter. We believe Q4 2023 further demonstrates the strength of IRadimed's product offerings and our ability to execute.
As this morning's press release announced, fourth quarter 2023 revenue came in at $17.5 million, representing a 17.4% increase over the fourth quarter of 2022. GAAP diluted earnings per share for the fourth quarter were $0.36, while non-GAAP diluted earnings were $0.39 per share, a 22% increase over Q4 '22. Our entire team's commitment, focus and can-do attitude pulls together to provide the winning performances we have achieved.